David Erbe
Alnylam Pharmaceuticals
15 Papers
21 Citations
David Erbe is an academic researcher from Alnylam Pharmaceuticals. The author has contributed to research in topics: Primary hyperoxaluria & Polyneuropathy. The author has an hindex of 6, co-authored 15 publications.
Chat about Author
Papers
Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial
Yaacov Frishberg,Georges Deschênes,Jaap W. Groothoff,Sally-Anne Hulton,Daniella Magen,Jérôme Harambat,William van’t Hoff,Ulrike Lorch,Dawn S. Milliner,John C. Lieske,Patrick Haslett,Pushkal Garg,Akshay Vaishnaw,Sandeep Talamudupula,Jiandong Lu,Bahru A. Habtemariam,David Erbe,Tracy L. McGregor,Pierre Cochat,Pierre Cochat +19 more
TL;DR: Lumasiran, an RNA interference therapeutic, suppresses glycolate oxidase, reducing hepatic oxalate production in patients with primary hyperoxaluria type 1.
61
Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry.
Margaret M. Parker,Scott M. Damrauer,Catherine Tcheandjieu,David Erbe,Emre Aldinc,Philip N. Hawkins,Julian D. Gillmore,Leland E. Hull,Julie A. Lynch,Jacob Joseph,Simina Ticau,Alexander O. Flynn-Carroll,Aimee M. Deaton,Lucas D. Ward,Themistocles L. Assimes,Themistocles L. Assimes,Philip S. Tsao,Philip S. Tsao,Kyong-Mi Chang,Daniel J. Rader,Kevin Fitzgerald,Akshay Vaishnaw,Gregory Hinkle,Paul Nioi +23 more
TL;DR: In this paper, the authors conducted a phenome-wide association study scanning 427 ICD diagnosis codes in UK Biobank participants of African ancestry and found that V122I carriers are at increased risk of polyneuropathy.
Mp12-14 safety and efficacy study of lumasiran, an investigational rna interference (rnai) therapeutic, in adult and pediatric patients with primary hyperoxaluria type 1 (ph1)
Yaacov Frishberg,Georges Deschênes,Pierre Cochat,Daniella Magen,Jaap W. Groothoff,Sally A. Hulton,Jérôme Harambat,William van’t Hoff,Bernd Hoppe,John C. Lieske,Tracy L. McGregor,Patrick Haslett,Sandeep Talamudupula,David Erbe,Dawn S. Milliner +14 more
TL;DR: PH1 is a genetic disorder characterized by hepatic overproduction of oxalate, which crystalizes with calcium in the urinary system to become toxic; this manifests with r... as mentioned in this paper.
10
Association of the Transthyretin Variant V122I With Polyneuropathy Among Individuals of African Descent
Margaret M. Parker,Scott M. Damrauer,Catherine Tcheandjieu,Catherine Tcheandjieu,David Erbe,Emre Aldinc,Philip N. Hawkins,Julian D. Gillmore,Leland E. Hull,Julie A. Lynch,Jacob Joseph,Simina Ticau,Alexander O. Flynn-Carroll,Aimee M. Deaton,Lucas D. Ward,Themistocles L. Assimes,Themistocles L. Assimes,Philip S. Tsao,Philip S. Tsao,Kyong-Mi Chang,Kyong-Mi Chang,Daniel J. Rader,Kevin Fitzgerald,Akshay Vaishnaw,Gregory Hinkle,Paul Nioi +25 more
TL;DR: V122I carriers, historically associated with a predominantly cardiac phenotype of hATTR amyloidosis, have a significantly increased risk of polyneuropathy.
Patent
Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
Querbes William,Fitzgerald Kevin,Bettencourt Brian,Abigail Liebow,David Erbe +4 more
- 09 Oct 2015
TL;DR: In this paper, double-stranded RNAi agents are used to inhibit the expression of a HA01 gene in a cell, such as a cell within a subject, e.g., a mammal, such a human having a HAO1 associated disorder.
8